BRPI0909633A2 - anticorpos anti-tyrp1 - Google Patents

anticorpos anti-tyrp1

Info

Publication number: BRPI0909633A2
Authority: BR; Brazil
Prior art keywords: tyrp1; antibodies; tyrp1 antibodies
Prior art date: 2008-03-12

Application number

BRPI0909633A

Other languages

English (en)

Inventor

Paul J Balderes

Xiaoqiang Kang

Original Assignee

Imclone Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-12

Filing date

2009-03-11

Publication date

2015-09-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909633(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-11 Application filed by Imclone Llc filed Critical Imclone Llc

2015-09-22 Publication of BRPI0909633A2 publication Critical patent/BRPI0909633A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0909633A 2008-03-12 2009-03-11 anticorpos anti-tyrp1 BRPI0909633A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6919908P	2008-03-12	2008-03-12
PCT/US2009/036739 WO2009114585A1 (en)	2008-03-12	2009-03-11	Anti-tyrp1 antibodies

Publications (1)

Publication Number	Publication Date
BRPI0909633A2 true BRPI0909633A2 (pt)	2015-09-22

Family

ID=40790741

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909633A BRPI0909633A2 (pt)	2008-03-12	2009-03-11	anticorpos anti-tyrp1

Country Status (19)

Country	Link
US (1)	US7951370B2 (pt)
EP (1)	EP2268672A1 (pt)
JP (1)	JP2011516041A (pt)
KR (1)	KR101203777B1 (pt)
CN (1)	CN101970500B (pt)
AR (1)	AR070821A1 (pt)
AU (1)	AU2009222998B2 (pt)
BR (1)	BRPI0909633A2 (pt)
CA (1)	CA2718289A1 (pt)
CL (1)	CL2009000567A1 (pt)
EA (1)	EA019517B1 (pt)
IL (1)	IL207581A0 (pt)
MX (1)	MX2010010021A (pt)
NZ (1)	NZ587305A (pt)
PE (1)	PE20091679A1 (pt)
TW (1)	TWI384997B (pt)
UA (1)	UA99339C2 (pt)
WO (1)	WO2009114585A1 (pt)
ZA (1)	ZA201006099B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2167540T3 (pl) *	2007-06-29	2018-07-31	F. Hoffmann-La Roche Ag	Mutant łańcucha ciężkiego prowadzący do ulepszonego wytwarzania immunoglobuliny
NZ723237A (en)	2014-02-07	2018-02-23	Dong Wha Pharm Co Ltd	Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
WO2016097300A1 (en)	2014-12-19	2016-06-23	Genmab A/S	Rodent bispecific heterodimeric proteins
RU2630647C1 (ru) *	2016-05-27	2017-09-11	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
GB201613167D0 (en)	2016-07-29	2016-09-14	Univ Southampton	Cancer and b-cell related disease therapy
WO2018075586A1 (en) *	2016-10-18	2018-04-26	Memorial Sloan-Kettering Cancer Center	Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
MX2019015053A (es) *	2017-06-14	2020-02-13	Adicet Bio Inc	Anticuerpos capaces de unirse a hla-a2/tyrd de forma restringida por hla y usos de estos.
RU2687609C1 (ru) *	2018-05-30	2019-05-15	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
CN112771076B (zh)	2018-09-27	2024-04-02	奥托路斯有限公司	嵌合抗原受体
JP7440509B2 (ja)	2018-11-09	2024-02-28	ベスイスラエルデアコネスメディカルセンター	Ｃｄｃｐ１－標的化療法
CN113621062B (zh) *	2018-12-21	2024-07-02	豪夫迈·罗氏有限公司	与cd3结合的抗体
WO2021046432A1 (en) *	2019-09-06	2021-03-11	The Regents Of The University Of California	Chimeric antigen receptors and related methods and compositions for the treatment of cancer
CN118284625A (zh) *	2021-11-26	2024-07-02	豪夫迈·罗氏有限公司	抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
WO2025104289A1 (en)	2023-11-17	2025-05-22	Medincell S.A.	Antineoplastic combinations
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4798790A (en) *	1985-07-18	1989-01-17	Sloan-Kettering Institute	Monoclonal antibody specific for a pigmentation associated antigen
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
DE3853515T3 (de)	1987-05-21	2005-08-25	Micromet Ag	Multifunktionelle proteine mit vorbestimmter zielsetzung.
IL89489A0 (en)	1988-03-09	1989-09-10	Hybritech Inc	Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503867A (ja)	1988-04-15	1990-11-15	プロテイン　デザイン　ラブズ　インコーポレーテッド	Ｉｌ‐２レセプター特異的キメラ抗体
CA1341411C (en)	1988-04-16	2002-12-17	Lutz Riechmann	Method for producing fv fragments in eukaryotic cells
IE20000918A1 (en)	1990-03-22	2001-05-30	Sloan Kettering Inst Cancer	GP75 As a Tumor Vaccine for Melanoma
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DE69233782D1 (de)	1991-12-02	2010-05-20	Medical Res Council	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
WO1993021319A1 (en)	1992-04-08	1993-10-28	Cetus Oncology Corporation	HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
WO1996040249A1 (en)	1995-06-07	1996-12-19	Sloan-Kettering Institute For Cancer Research	Therapeutic uses of ta99
US5840839A (en)	1996-02-09	1998-11-24	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
CN1294517A (zh) *	1997-11-14	2001-05-09	欧洲细胞技术有限公司	具有合成可变区和修饰特异性的免疫球蛋白分子
AU2001274853B2 (en) *	2000-05-16	2007-03-22	Bolder Biotechnology, Inc.	Methods for refolding proteins containing free cysteine residues
AU2005299716B2 (en) *	2004-10-22	2012-09-06	Amgen Inc.	Methods for refolding of recombinant antibodies

2009
- 2009-03-11 AU AU2009222998A patent/AU2009222998B2/en not_active Ceased
- 2009-03-11 UA UAA201010912A patent/UA99339C2/ru unknown
- 2009-03-11 CA CA2718289A patent/CA2718289A1/en not_active Abandoned
- 2009-03-11 TW TW098107909A patent/TWI384997B/zh not_active IP Right Cessation
- 2009-03-11 EP EP09719438A patent/EP2268672A1/en not_active Withdrawn
- 2009-03-11 KR KR1020107020296A patent/KR101203777B1/ko not_active Expired - Fee Related
- 2009-03-11 EA EA201071068A patent/EA019517B1/ru not_active IP Right Cessation
- 2009-03-11 JP JP2010550830A patent/JP2011516041A/ja active Pending
- 2009-03-11 BR BRPI0909633A patent/BRPI0909633A2/pt not_active IP Right Cessation
- 2009-03-11 NZ NZ587305A patent/NZ587305A/en not_active IP Right Cessation
- 2009-03-11 AR ARP090100858A patent/AR070821A1/es not_active Application Discontinuation
- 2009-03-11 CN CN2009801085150A patent/CN101970500B/zh not_active Expired - Fee Related
- 2009-03-11 CL CL2009000567A patent/CL2009000567A1/es unknown
- 2009-03-11 WO PCT/US2009/036739 patent/WO2009114585A1/en not_active Ceased
- 2009-03-11 PE PE2009000356A patent/PE20091679A1/es not_active Application Discontinuation
- 2009-03-11 US US12/401,800 patent/US7951370B2/en not_active Expired - Fee Related
- 2009-03-11 MX MX2010010021A patent/MX2010010021A/es active IP Right Grant
2010
- 2010-08-12 IL IL207581A patent/IL207581A0/en unknown
- 2010-08-26 ZA ZA2010/06099A patent/ZA201006099B/en unknown

Also Published As

Publication number	Publication date
CL2009000567A1 (es)	2010-02-26
AR070821A1 (es)	2010-05-05
EP2268672A1 (en)	2011-01-05
NZ587305A (en)	2012-05-25
KR101203777B1 (ko)	2012-11-21
JP2011516041A (ja)	2011-05-26
MX2010010021A (es)	2011-02-15
KR20100113631A (ko)	2010-10-21
CN101970500A (zh)	2011-02-09
EA201071068A1 (ru)	2011-04-29
TWI384997B (zh)	2013-02-11
IL207581A0 (en)	2010-12-30
CN101970500B (zh)	2013-08-14
ZA201006099B (en)	2012-01-25
AU2009222998A1 (en)	2009-09-17
US7951370B2 (en)	2011-05-31
WO2009114585A1 (en)	2009-09-17
PE20091679A1 (es)	2009-11-04
EA019517B1 (ru)	2014-04-30
UA99339C2 (ru)	2012-08-10
AU2009222998B2 (en)	2013-05-23
US20090232823A1 (en)	2009-09-17
CA2718289A1 (en)	2009-09-17
TW200944232A (en)	2009-11-01

Publication	Publication Date	Title
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
IL212175B (en)	2019-08-29	Muc1* antibodies
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
PT2406284T (pt)	2016-09-29	Anticorpos anti-bcma
BRPI0917148A2 (pt)	2015-12-01	anticorpos anti-cd5
BRPI0912173A2 (pt)	2016-07-26	anticorpos anti-flt3
BRPI0923359A2 (pt)	2015-07-21	Anticorpos anti-igf
BRPI0907532A2 (pt)	2015-07-28	Anticorpos anti-c5ar humanizados
BRPI0922800A2 (pt)	2015-12-22	anticorpos c-met
DE602009000234D1 (de)	2010-11-11	msignals
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
HRP20150224T1 (xx)	2015-06-05	Anti-mif protutijela
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
EP2262831A4 (en)	2012-07-25	ANTI-properdin antibody
DE602008003972D1 (de)	2011-01-27	Sitzrücklehnungsmechanismus
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
DE602008003521D1 (de)	2010-12-30	Sitzrücklehnungsmechanismus
EP2207803A4 (en)	2010-11-24	Cd9-specific human antibodies
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
DE112009000183A5 (de)	2011-02-03	Sicherheitsvorreiber

Legal Events

Date	Code	Title	Description
2016-05-24	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-09-27	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2368 DE 24-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.